Safety and Efficacy of Intravenous Acetaminophen (IV APAP) in Adult Inpatients: Complete Statistical Analysis

1. Trial at a Glance

This page covers the registry results for Safety and Efficacy of Intravenous Acetaminophen (IV APAP) in Adult Inpatients (NCT00598559), a randomized phase 3 study. The primary outcome is Number of Subjects Reporting at Least One Treatment-Emergent Adverse Event (TEAE)..

2. Clinical Question

3. Trial Design

The registry record describes a Phase III, multicenter, open-label, prospective, repeated-dose, randomized, controlled study with a parallel-group design. It is listed as completed. Enrollment was 213. The study began in 2008-01, and primary completion was recorded in 2008-11. The sponsor was Mallinckrodt. These record details describe the trial structure and timing, but do not establish how participants were recruited or how the allocation sequence was generated.

Participants were assigned to intravenous acetaminophen at 1 g every 6 hours, intravenous acetaminophen at 650 mg every 4 hours, or standard of care. The two intravenous regimens were delivered over five days according to the brief summary. Standard of care was not a single fixed drug: investigators could select any medication considered appropriate, including acetaminophen-containing products, except intravenous acetaminophen. That flexibility makes the comparator clinically pragmatic but also means that the control treatment could vary between participants.

The study was open-label, with no masking. Participants and investigators therefore were not blinded to assigned treatment, according to the record. The record does not report the method of randomization, allocation concealment, site count, eligibility criteria in detail, or the rationale for the selected treatment schedules. The original sample-size assumptions and statistical design plan are not reported in the registry record.

The main posted outcome concerns treatment-emergent adverse events, with a stated observation window beginning at first dose or randomization and extending through Day 7–12 follow-up. Two additional outcomes assess participant satisfaction with side effects and with study treatments overall. The record posts results for these outcomes but reports no analyses as formal registry analyses. Thus, the posted group summaries and comparisons can be read descriptively, while details of the original prespecified inferential strategy are not reported in the registry record.

4. Participant Flow and Accounting

The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.

Overall Study

Reasons for not completing this period:

Analysis population for the primary outcome, as defined in the registry: Safety analyses were conducted using the mITT population, defined as subjects who were randomized to the IV acetaminophen groups and who received at least one dose of IV acetaminophen, and all subjects assigned to the SOC group.

5. Baseline Characteristics

The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.

6. Primary Endpoint

The registry lists the primary outcome as Number of Subjects Reporting at Least One Treatment-Emergent Adverse Event (TEAE)., measured over T0 (first dose of IV APAP or randomization to SOC group) to Day 7 - 12 Follow-up.

The primary endpoint is the number of participants reporting at least one treatment-emergent adverse event. A treatment-emergent adverse event is defined in the registry record as an adverse event occurring on or after the first dose of study medication. For the standard-of-care group, the stated start point is randomization. The timeframe continues through Day 7–12 follow-up.

This kind of endpoint is used to summarize whether participants experienced any qualifying event during the observation window. Counting each participant once for the endpoint avoids treating multiple events in the same participant as multiple people, although the record does not provide a participant-level event history in the posted primary results. The endpoint is a broad safety measure: it does not distinguish mild from severe events, identify event duration, or establish that treatment caused an event. Those questions require additional event-level and attribution information.

The endpoint is reported as counts: 77 of 92 participants in the 1 g every 6 hours group, 86 of 91 in the 650 mg every 4 hours group, and 26 of 30 in standard of care were recorded as having at least one event. The safety population definition is not identical to simply describing everyone randomized to an intravenous regimen: participants in those groups had to receive at least one dose, whereas all assigned standard-of-care participants were included. This difference in the stated population definition matters when interpreting group comparisons.

The record also reports participant satisfaction outcomes, but these are secondary measures and do not change the meaning of the primary safety endpoint. The registry record does not report a primary efficacy endpoint for pain or fever in the posted results.

7. Results Posted in the Registry

• IV Acetaminophen 1 g q6h: 83.7% (77/92) versus 86.7% (26/30) on control; risk difference -3.0 percentage points (95% CI -17.3 to 11.3), risk ratio 0.97 (0.82–1.14); unadjusted two-proportion z-test p = 0.697.
• IV Acetaminophen 650 mg q4h: 94.5% (86/91) versus 86.7% (26/30) on control; risk difference 7.8 percentage points (95% CI -5.2 to 20.9), risk ratio 1.09 (0.94–1.27); unadjusted two-proportion z-test p = 0.156.

8. Secondary Efficacy Endpoints

The registry also posts results for secondary outcomes. For each outcome below, the endpoint type, the test applied to the posted summary statistics, the result and its interpretation are given in turn. Secondary endpoints are usually not adjusted for multiple testing, so they support rather than confirm the primary finding.

Subject Global Evaluation of the Level of Satisfaction With Side Effects Related to Study Treatments

• Endpoint type: Continuous: a mean value per participant, compared as a difference in means.
• Test: Unadjusted two-sample z-test for the difference in means, using the posted standard deviations.
• Result:
  • IV Acetaminophen 1 g q6h: mean 2.50 versus 2.00 on control; difference 0.50 (95% CI 0.12 to 0.88), standardized effect d = 0.62; z-test p = 0.010.
  • IV Acetaminophen 650 mg q4h: mean 2.50 versus 2.00 on control; difference 0.50 (95% CI 0.13 to 0.87), standardized effect d = 0.69; z-test p = 0.007.
• Interpretation:
  • The 95% confidence interval excludes no difference, so the mean is statistically higher for IV Acetaminophen 1 g q6h than for the control. This is an unadjusted, secondary comparison, so it is suggestive rather than confirmatory.
  • The 95% confidence interval excludes no difference, so the mean is statistically higher for IV Acetaminophen 650 mg q4h than for the control. This is an unadjusted, secondary comparison, so it is suggestive rather than confirmatory.

Subject Global Evaluation of the Level of Satisfaction With Study Treatments Looking Back Over the Entire Treatment Period.

• Endpoint type: Continuous: a mean value per participant, compared as a difference in means.
• Test: Unadjusted two-sample z-test for the difference in means, using the posted standard deviations.
• Result:
  • IV Acetaminophen 1 g q6h: mean 2.40 versus 2.20 on control; difference 0.20 (95% CI -0.09 to 0.49), standardized effect d = 0.28; z-test p = 0.170.
  • IV Acetaminophen 650 mg q4h: mean 2.30 versus 2.20 on control; difference 0.10 (95% CI -0.19 to 0.39), standardized effect d = 0.14; z-test p = 0.494.
• Interpretation:
  • The 95% confidence interval includes no difference, so these data do not show a statistically significant difference between IV Acetaminophen 1 g q6h and the control. The interval gives the range of effects that remain compatible with the data.
  • The 95% confidence interval includes no difference, so these data do not show a statistically significant difference between IV Acetaminophen 650 mg q4h and the control. The interval gives the range of effects that remain compatible with the data.

The secondary outcomes concern participants’ satisfaction with side effects related to study treatments and satisfaction with the treatments overall. Their timing differs: the side-effects assessment was at the end of Day 5 before discharge, whereas the overall-treatment assessment asked participants to look back over the study period at Day 7. The registry record reports group means and standard deviations, and unadjusted comparisons with standard of care.

Across the posted summaries, the intravenous groups have higher mean scores than standard of care for both outcomes. The comparison estimates are not equally precise, and the posted intervals and unadjusted p-values differ between outcomes. These results describe the observed satisfaction scores; without scale anchors, it is not possible to determine from the record what a given score means in practical terms or how large a difference participants would consider important.

These measures address participants’ evaluations, not the occurrence of treatment-emergent adverse events itself. Satisfaction with side effects is conceptually related to tolerability, while overall satisfaction can reflect a wider set of experiences. Neither measure can substitute for the primary event count, and an apparent difference in satisfaction does not resolve the uncertainty in the safety comparison. The outcomes also use different follow-up times and different numbers of participants, so their estimates should not be treated as interchangeable.

The record reports two secondary outcomes and does not report a multiplicity adjustment or confirmatory hierarchy. Testing multiple outcomes and comparisons increases the chance that at least one result appears notable by chance. In addition, the study was open-label, so participant expectations and knowledge of assigned treatment could influence satisfaction ratings. These features mean that unadjusted secondary results carry less evidential weight than a prespecified, multiplicity-controlled analysis would. They are best read as descriptive patterns that may motivate further study, not as standalone confirmation of a treatment advantage.

Secondary outcomes registered for this trial, for reference (only those above were recalculated):

• Subject Global Evaluation of the Level of Satisfaction With Side Effects Related to Study Treatments
• Subject Global Evaluation of the Level of Satisfaction With Study Treatments Looking Back Over the Entire Treatment Period.

9. Statistical Interpretation

10. Statistical Methods Explained

Random allocation is intended to make treatment groups comparable on average, including for factors that are not measured. It does not ensure that groups are identical in a particular trial, especially when group sizes are modest. The registry record identifies the study as randomized and parallel-group, but does not report the sequence-generation method, allocation concealment, or detailed randomization procedures. Those omissions limit assessment of how allocation was implemented.

How should a risk difference be read?

A risk difference expresses the difference between the proportion of participants with an event in one group and the corresponding proportion in the comparison group. A value of zero represents no observed difference. Negative and positive values indicate opposite directions depending on the order of groups used in the comparison. The primary comparisons use standard of care as the reference. The estimate for 1 g every 6 hours is -0.030, and the estimate for 650 mg every 4 hours is 0.078. These are unadjusted estimates based on posted summary counts, not results of a reported adjusted model.

The confidence interval describes a range of values compatible with the data under the method used to calculate it. It reflects statistical uncertainty, not the range of individual outcomes and not a probability that the true value lies within that specific interval. Both primary confidence intervals include zero and are broad enough to allow effects in either direction. The unadjusted p-values, 0.697 and 0.156, describe the compatibility of the observed data with a no-difference null under their calculation assumptions. They do not measure the probability that the null hypothesis is true or the size of a treatment effect.

What does open-label mean for interpretation?

Open-label means that masking was not used, as recorded for this study. Awareness of treatment assignment can influence reporting, assessment, care decisions, and participant expectations, particularly for subjective outcomes such as satisfaction and for adverse events that depend on recognition or reporting. Randomization does not remove all possible consequences of unmasked treatment. The record does not describe procedures intended to reduce these risks.

The comparator also requires care in interpretation. Standard of care could be any medication the investigator considered appropriate, including products containing acetaminophen but not intravenous acetaminophen. The comparison is therefore between assigned regimens and a flexible usual-care group, not necessarily between each regimen and one identical control treatment. Variation in control medication can affect both clinical context and the interpretation of group differences.

Why does the analysis population matter?

The primary safety outcome uses the record’s mITT definition: participants randomized to intravenous acetaminophen groups who received at least one dose, plus all participants assigned to standard of care. This is not described as a complete intention-to-treat analysis of every randomized participant in every arm. Excluding intravenous-assigned participants who did not receive a dose can alter the composition of the analyzed groups, while retaining all standard-of-care participants follows a different inclusion rule. The registry record does not report the number or outcomes of any randomized participants excluded from the intravenous groups.

The endpoint is binary at the participant level: whether a participant had at least one treatment-emergent event. A binary summary is easy to interpret, but it discards information about the number, timing, recurrence, and severity of events. For example, two participants who each meet the endpoint may have very different event experiences. The primary posted summaries do not supply those details.

For continuous secondary endpoints, the record gives group means and standard deviations, with mean differences and confidence intervals in the posted comparisons. A mean difference describes the difference in average scale values between groups. Its practical meaning depends on the scale’s range and anchors, which are not reported in the registry record. A standard deviation describes spread among individual measurements; it is not the uncertainty around the mean itself. The posted unadjusted p-values for these outcomes are not accompanied by reported registry analysis details.

What can the p-values and estimates establish?

Statistical significance is not the same as clinical importance, and a non-small p-value does not establish equivalence. Interpreting an estimate requires its magnitude, uncertainty, endpoint definition, and the study context. Here, the primary confidence intervals cover both directions around zero, so the data do not yield a precise estimate of the difference in event reporting. The record does not report a prespecified equivalence margin or noninferiority margin.

There are multiple comparisons: two intravenous regimens are compared with standard of care, and two secondary satisfaction outcomes are also reported. Repeated testing can increase the chance of at least one apparently notable result when there is no true effect. The registry record does not report a multiplicity adjustment or a hierarchy for interpreting outcomes. The secondary comparisons should therefore be treated as exploratory or descriptive rather than as independent confirmatory evidence.

Finally, the planning illustrations are calculations based on observed effects and stated assumptions, not a record of the original trial design. The original sample-size justification, target power, interim analyses, and full statistical plan are not reported in the registry record. No number of participants in a planning illustration should be mistaken for an observed trial result or for evidence that the completed trial had a particular power.

11. Confidence Intervals and Precision

Precision is reflected in the width of a confidence interval: narrower intervals indicate less statistical uncertainty about the estimated contrast, while wider intervals leave a broader range of values compatible with the data. For the primary comparison of 1 g every 6 hours with standard of care, the risk difference is -0.030 and its 95% confidence interval runs from -0.173 to 0.113. For 650 mg every 4 hours versus standard of care, the estimate is 0.078 and the interval runs from -0.052 to 0.209. Each interval crosses zero, so neither comparison provides a precise direction of difference.

The standard-of-care group includes 30 participants in the primary safety summaries, compared with 92 and 91 in the intravenous groups. A relatively small comparison group generally contributes less information to an estimate and can widen uncertainty. This helps explain why the intervals do not sharply distinguish among plausible effects, although the record does not report a precision target or design calculation for these comparisons.

A confidence interval is not a guarantee that the true effect lies within the stated endpoints, nor does it describe individual participant variability. It quantifies uncertainty in an estimated group contrast under the method used. The registry record does not report formal registry analyses or enough methodological detail to assess every modeling choice behind the recalculated comparisons. These intervals should therefore be read as unadjusted statistical summaries, not as a full sponsor analysis.

For the satisfaction outcomes, the posted mean-difference intervals also vary in width and include or exclude zero according to their respective estimates. Their precision depends on the numbers contributing to each outcome and the spread of scale values. Because scale anchors and missing-data methods are not reported, the intervals alone cannot establish the practical importance of a mean difference. Statistical precision and clinical interpretation are separate questions.

12. Planning a Similar Trial: Sample Size

This is a planning illustration, not a re-evaluation of the original trial. It asks: if a new study wanted to detect a difference like the one observed, or a smaller one, how large would it need to be? It is deliberately not “observed power” of the finished trial, which is not a meaningful quantity.

The planning figures are illustrations of how many participants per arm might be needed under the stated assumptions to detect a chosen fraction of an observed effect. The figures are not the number enrolled in this study and are not evidence about the trial’s actual statistical power. For the binary primary endpoint and the satisfaction outcomes, the planning entries are participants per arm, not total event counts. The stated planning assumptions are a two-sided significance level of 0.05, equal allocation between the two arms, and a normal approximation. The effect to detect is set to the listed fraction of the observed effect. The original trial’s own design assumptions are not reported in the registry record.

The 80% power column gives the planned participants per arm for a design that would have an 80% chance of detecting the specified effect if that effect were the true one and the planning assumptions held. The 90% power column gives the corresponding per-arm planning figure for a 90% chance. These are design probabilities, not probabilities that a result is true or that an observed finding is reliable. For any one comparison, the entries change as the assumed target effect changes.

Planning for 75% of the observed effect or 50% of the observed effect requires more participants than planning for 100% of the observed effect: smaller effects are harder to distinguish from random variation. The observed effect itself can be unstable, particularly when estimated from small groups, so such illustrations should not be treated as a definitive future-trial recommendation. They use the posted effect as a starting point rather than an independently justified clinically important difference. These figures are not observed power.

13. How the Sample Size Is Derived

Power is the probability that a study of a given size rejects the null hypothesis when a specific true effect exists. It depends on four things: the effect to detect, the variability of the outcome, the significance level (here a two-sided α of 0.05, so z_1−α/2 = 1.960) and the desired power (z_1−β = 0.842 for 80% and 1.282 for 90%).

Formula

n is the number of participants in each arm, p₀ and p₁ are the control and treatment proportions, and p̄ is their average.

Worked calculation for this trial

1. Control proportion p₀ = 0.867; treatment proportion p₁ = 0.837; average p̄ = 0.852.
2. First term: z_1−α/2 × √[2p̄(1−p̄)] = 1.96 × 0.5025 = 0.9848.
3. Second term: z_1−β × √[p₀(1−p₀) + p₁(1−p₁)] = 0.842 × 0.5020 = 0.4225.
4. n = (0.9848 + 0.4225)² / (-0.0297)² = 2,243.7, rounded up to 2,244 participants per arm for 80% power.

The smaller-effect rows in the table above repeat the same calculation with the effect multiplied by 0.75 and 0.5 (for ratios, applied to the logarithm of the ratio).

R code

alpha <- 0.05
z_a   <- qnorm(1 - alpha / 2)          # two-sided
p0 <- 0.866666666666667                          # control proportion
p1 <- 0.83695652173913                          # treatment proportion
n_per_arm <- function(power, frac = 1) {
  q1 <- p0 + (p1 - p0) * frac               # smaller effect = fraction of the observed difference
  pbar <- (p0 + q1) / 2
  z_b <- qnorm(power)
  ceiling(round((z_a * sqrt(2 * pbar * (1 - pbar)) + z_b * sqrt(p0 * (1 - p0) + q1 * (1 - q1)))^2 / (q1 - p0)^2, 6))
}
for (f in c(1, 0.75, 0.5))
  cat(sprintf("%3.0f%% of observed effect: n per arm = %s (80%% power), %s (90%% power)\n", 100 * f,
              format(n_per_arm(0.80, f), big.mark = ","), format(n_per_arm(0.90, f), big.mark = ",")))

# Check against R's built-in function (unrounded n per arm)
cat("power.prop.test:", round(power.prop.test(p1 = p0, p2 = p1, power = 0.80)$n, 1), "\n")

# Simulation: how often does the z-test reject at the 80%-power sample size?
set.seed(598559)
n    <- n_per_arm(0.80)
reps <- 20000
x0 <- rbinom(reps, n, p0); x1 <- rbinom(reps, n, p1)
ph <- (x0 + x1) / (2 * n)
z  <- ((x1 - x0) / n) / sqrt(ph * (1 - ph) * 2 / n)
cat(sprintf("Simulated power at n = %s per arm: %.3f (%d replicates)\n", format(n, big.mark = ","), mean(abs(z) > z_a, na.rm = TRUE), reps))

Output from running the code

100% of observed effect: n per arm = 2,244 (80% power), 3,004 (90% power)
 75% of observed effect: n per arm = 3,907 (80% power), 5,230 (90% power)
 50% of observed effect: n per arm = 8,603 (80% power), 11,516 (90% power)
power.prop.test: 2243.7 
Simulated power at n = 2,244 per arm: 0.802 (20000 replicates)

The simulation draws many pairs of event counts at the planned sample size and counts how often the two-proportion z-test rejects the null. It should land close to the target power; at very small required sample sizes it can fall below it, because the normal approximation is rough there.

14. Multiplicity, Missing Data and Analysis Populations

The registry record lists one primary safety endpoint and two secondary satisfaction outcomes, with comparisons of each intravenous regimen against standard of care. This creates multiple opportunities to observe an apparently notable result. When many outcomes or comparisons are examined, the chance of at least one small p-value can rise even if no underlying differences exist. Statistical approaches such as adjustment procedures or a prespecified testing hierarchy can address this issue, but the registry record does not report whether either was used. The posted comparisons are described with unadjusted p-values, so they should not be interpreted as multiplicity-adjusted evidence.

The record reports zero formal analyses. It does not provide a complete statistical analysis plan, specify which analyses were prespecified, describe interim analyses, or state whether any interim stopping rules were used. These details are not reported in the registry record; they should not be inferred from the endpoint listings or the presence of posted summary comparisons. The original sample-size justification and the intended handling of multiple comparisons are also not reported.

For the primary safety endpoint, the mITT population includes participants randomized to an intravenous acetaminophen group who received at least one dose and all participants assigned to standard of care. The record does not report how many randomized participants failed to meet the intravenous-group inclusion rule or what happened to their outcome data. It also does not describe missing-data methods, imputation, sensitivity analyses, or whether outcome data were complete for all participants in the stated analysis population.

For the satisfaction outcomes, the numbers contributing to each group are smaller than the primary safety group counts, but the reasons for noncontribution are not reported. The record does not say whether these differences reflect discharge timing, missed assessments, other exclusions, or missing responses. Without that information, the possibility of selection related to who completed a satisfaction measure cannot be assessed. These uncertainties matter because analyses of observed cases can be affected when missingness is related to treatment experience or outcome values.

15. Safety Results

The registry reports serious adverse events as affected participants divided by participants at risk.

Other (non-serious) adverse events

Participants with at least one non-serious event at or above the registry's 5% reporting threshold.

Most frequent serious adverse event terms

Most frequent non-serious adverse event terms

Serious events with the highest arm-level rate: dyspnoea (3.3%), postoperative ileus (3.3%), sepsis (3.3%), hepatic enzyme increased (2.2%), postoperative wound infection (2.2%).

The serious adverse event summaries report 14 in the 1 g every 6 hours group, 11 in the 650 mg every 4 hours group, and 3 in standard of care. The corresponding group sizes at risk are 92, 91, and 30. These figures should be read as the registry’s reported serious-event counts, not as a comparison that establishes causation or a difference in safety. The record does not provide a serious-event comparison estimate or confidence interval.

Among the listed serious adverse event terms, the registry reports Dyspnoea, Postoperative ileus, and Sepsis at 3.3% each; Hepatic enzyme increased and Postoperative wound infection at 2.2% each; and Abscess at 1.1%. The record does not provide further detail on event timing, severity grading, attribution, or whether terms could occur more than once in a participant. Death counts are not reported in the registry record.

The other adverse-event summaries report 60, 68, and 18 for the respective groups, with groups at risk of 92, 91, and 30. They should not be conflated with the primary endpoint counts or with serious-event counts. The registry record does not provide a detailed breakdown of these other events in the posted summaries. Differences in group size, the flexible standard-of-care treatment, open-label conduct, and the absence of inferential safety analyses all limit comparative conclusions.

16. What the Result Does, and Does Not, Mean

The posted primary results show that many participants in each group reported at least one treatment-emergent adverse event during the stated observation period. The unadjusted comparisons have confidence intervals that include zero and allow effects in either direction. Thus, the results do not establish a clear difference in event reporting between either intravenous acetaminophen regimen and standard of care, and they do not establish equivalence. The intervals are also not narrow enough to rule out potentially meaningful differences based on a margin defined in the registry record; no such margin is reported.

The outcome is a broad count of participants with at least one event. It does not reveal the number of events per participant, their duration, severity, timing in detail, or whether investigators considered them related to treatment. Serious adverse events are listed separately, but the registry record does not report a formal comparison of serious-event risks or deaths. The safety results therefore cannot be reduced to a claim that one regimen is safer or more hazardous.

The study’s randomized design supports a comparative framework, but interpretation is affected by open-label conduct, the flexible standard-of-care comparator, and the stated safety-population definition. The registry record does not report enough detail to determine how randomization was implemented, how missing data were handled, or whether the posted comparisons match a prespecified analysis plan.

The secondary satisfaction results describe participant evaluations at two different times. They do not establish how effective the treatments were for acute pain or fever. The posted primary endpoint is safety-focused, and no primary efficacy result is reported in the registry record. The findings should therefore be understood as a limited account of adverse-event reporting and satisfaction in this study, rather than as a complete assessment of the benefits and risks of intravenous acetaminophen.

These observations apply to the enrolled adult inpatients and the study conditions recorded. The registry record does not establish how well they generalize to other populations, treatment settings, doses, or durations. A lack of a clearly separated comparison in these data should not be mistaken for proof that groups are identical.

17. Why This Trial Matters Statistically

This trial illustrates why a randomized design and an imprecise result can coexist. Randomization supports a fair comparison in principle, but the uncertainty in an estimate still depends on the amount of information available and how outcomes are measured. The standard-of-care group was smaller than either intravenous acetaminophen group, and the primary confidence intervals remain broad and include zero. A point estimate alone would conceal that uncertainty.

The primary endpoint also demonstrates how a binary safety summary trades detail for simplicity. Counting participants with at least one treatment-emergent adverse event gives a straightforward group-level measure, but does not distinguish a single mild event from multiple or serious events. Separate adverse-event summaries add context, yet the registry record does not provide formal comparative analyses for those outcomes. Statistical summaries are only as informative as the endpoint definitions and supporting detail permit.

The study also has a flexible comparator and open-label design. Standard of care could include different medications, and treatment knowledge may affect reporting or subjective assessments. These are not reasons to dismiss the data, but they define what the comparison represents and what uncertainties remain. The satisfaction outcomes further show why multiple endpoints and unadjusted tests need cautious interpretation: a pattern of observed mean differences is not automatically confirmatory evidence.

Finally, planning calculations derived from observed effects can help illustrate how uncertainty and target effect size relate to future sample requirements, but they are not a substitute for a prospectively justified design. The original design assumptions and analysis plan are not reported in the registry record. The distinction between observed results, unadjusted recalculations, and planning illustrations is central to reading this trial responsibly.

18. Limitations

• The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
• Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.

The primary analysis population is defined differently for the intravenous groups and standard of care: intravenous-assigned participants had to receive at least one dose, while all standard-of-care participants were included. The registry record does not report whether any randomized participants were excluded under this rule, why they were excluded, or their outcomes. The effect of this population definition on the comparisons cannot be assessed from the posted record.

The standard-of-care group could receive any medication the investigator considered appropriate, including acetaminophen-containing products other than intravenous acetaminophen. As a result, the comparator is not one fixed treatment. The record does not describe the medications used, their distribution, or whether treatment varied by site or clinical circumstance. This limits the specificity of the treatment contrast.

The study was open-label. The record does not describe blinded outcome assessment or other measures to limit the influence of treatment awareness on event reporting or satisfaction ratings. The satisfaction outcomes also lack reported scale anchors and interpretation thresholds. Their numerical differences therefore cannot be translated into a clear judgment about practical importance from the registry record alone.

The registry record reports no formal analyses, and it does not describe missing-data handling, multiplicity control, interim analyses, or the original sample-size rationale. The satisfaction outcomes have fewer observations than the primary safety summaries, but reasons for this are not reported. Serious-event summaries are posted without a comparative estimate, while deaths are not reported. These omissions leave important details about the completeness and analysis of safety information unresolved.

Finally, enrollment and the group sizes limit the precision of comparisons, particularly given the smaller standard-of-care group. The primary endpoint is broad and does not capture event severity or recurrence. These limitations make the results most useful as descriptions of the posted groups and estimates, rather than as definitive comparative evidence.

19. Related Tutorials

20. Related Statistical Calculators

21. Sources

• ClinicalTrials.gov: Safety and Efficacy of Intravenous Acetaminophen (IV APAP) in Adult Inpatients — NCT00598559.
• Registry record last updated 2016-10-21; status last verified 2016-09.
• Results first posted 2010-12-10.
• Data retrieved from ClinicalTrials.gov on 2026-11-09.
• Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.

22. Record Summary

NCT00598559 is a completed Phase III, randomized, open-label, parallel-group study of repeated-dose intravenous acetaminophen in adult inpatients with acute pain or fever. The registry record reports enrollment of 213 and compares 1 g every 6 hours and 650 mg every 4 hours with investigator-selected standard of care. The primary endpoint counts participants with at least one treatment-emergent adverse event through the stated follow-up period.

Posted event counts were 77 of 92, 86 of 91, and 26 of 30, respectively. Both unadjusted risk-difference confidence intervals include zero. Two secondary outcomes report satisfaction with side effects and overall treatment satisfaction. The record reports no formal analyses, and details of the original statistical plan, missing-data methods, multiplicity handling, and original sample-size justification are not reported in the registry record. The results support a descriptive reading with substantial uncertainty, rather than a definitive comparative conclusion.